News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
AKESO Jumps Up 5% as Nomura Upgrades Stock to Buy; Jefferies Says HARMONI-6 Way Beyond Forecast
AKESO (09926.HK) announced the results of its HARMONI-6 clinical trial. Stretching last Friday (29th)'s rally, the stock opened 9.23% higher today (1st) and once spiked 12.3% t...
Reset
Send
The window will close in 5 seconds
AKESO Jumps Up 5% as Nomura Upgrades Stock to Buy; Jefferies Says HARMONI-6 Way Beyond Forecast
Close
Recommend
9
Positive
10
Negative
6
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

AKESO (09926.HK)  -3.900 (-3.662%)    Short selling $1.01B; Ratio 24.511%   announced the results of its HARMONI-6 clinical trial. Stretching last Friday (29th)'s rally, the stock opened 9.23% higher today (1st) and once spiked 12.3% to a peak of HKD132.6 in early trading. With gains later narrowed, it last quoted at HKD124.1, up 5.08%, with turnover surging to 31.5814 million shares, involving HKD3.961 billion.

Nomura published a research report stating that AKESO announced encouraging results from the HARMONI-6 clinical trial, boosting sentiment across the sector and casting a strong positive impact for both the company and the industry. The broker believed the successful data from HARMONI-6 increases the probability of success for the HARMONI-3 clinical trial. It upgraded AKESO from Neutral to Buy, while slightly lowering the TP to HKD142.5 from HKD142.75.

Related News CICC: Focus on Positive Capital Flow Impact from Index Review on BEONE MEDICINES (06160.HK), J&T EXPRESS-W (01519.HK), KNOWLEDGE ATLAS (02513.HK) and MINIMAX-W (00100.HK)
Jefferies also noted that data from the HARMONI-6 China clinical trial showed an overall survival (OS) hazard ratio (HR) of 0.66, notably better than expected. Ivonescimab recorded a median overall survival (mOS) of 27.9 months, with survival benefits widening over time and remaining consistent across different PD-L1 expression subgroups. Meanwhile, no new safety signals were identified in the clinical trial. The broker maintained its Buy rating and TP of HKD226 on the company.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-02 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.